tiprankstipranks
Trending News
More News >
Ajanta Pharma Limited (IN:AJANTPHARM)
:AJANTPHARM
India Market
Advertisement

Ajanta Pharma Limited (AJANTPHARM) Stock Forecast & Price Target

Compare
3 Followers
See the Price Targets and Ratings of:

AJANTPHARM Financial Forecast

AJANTPHARM Earnings Forecast

Next quarter’s earnings estimate for AJANTPHARM is ₹20.20 with a range of ₹20.20 to ₹20.20. The previous quarter’s EPS was ₹20.43. AJANTPHARM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 47.78% of the time in the same period. In the last calendar year AJANTPHARM has Outperformed its overall industry.
Next quarter’s earnings estimate for AJANTPHARM is ₹20.20 with a range of ₹20.20 to ₹20.20. The previous quarter’s EPS was ₹20.43. AJANTPHARM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 47.78% of the time in the same period. In the last calendar year AJANTPHARM has Outperformed its overall industry.

AJANTPHARM Sales Forecast

Next quarter’s sales forecast for AJANTPHARM is ₹13.28B with a range of ₹13.27B to ₹13.29B. The previous quarter’s sales results were ₹13.03B. AJANTPHARM beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 48.29% of the time in the same period. In the last calendar year AJANTPHARM has Outperformed its overall industry.
Next quarter’s sales forecast for AJANTPHARM is ₹13.28B with a range of ₹13.27B to ₹13.29B. The previous quarter’s sales results were ₹13.03B. AJANTPHARM beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 48.29% of the time in the same period. In the last calendar year AJANTPHARM has Outperformed its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on IN:AJANTPHARM
TipRanks AITipRanks
Not Ranked
TipRanks
₹2,980
Buy
13.93%
Upside
Reiterated
08/05/25
Ajanta Pharma Limited demonstrates strong financial performance, which is the primary driver of its overall score. While the technical analysis indicates a neutral trend, the company's solid valuation metrics support a positive outlook. The lack of significant earnings call data or notable corporate events means these factors do not affect the score.
Jefferies Analyst forecast on IN:AJANTPHARM
Alok DalalJefferies
Jefferies
₹2,850₹3,140
Buy
20.04%
Upside
Reiterated
04/30/25
Ajanta Pharma (AJP:IN) PT Raised to INR3,140 at JefferiesJefferies analyst Alok Dalal raised the price target on Ajanta Pharma (AJP:IN) to INR3,140.00 (from INR2,850.00) while maintaining a Buy rating.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on IN:AJANTPHARM
TipRanks AITipRanks
Not Ranked
TipRanks
₹2,980
Buy
13.93%
Upside
Reiterated
08/05/25
Ajanta Pharma Limited demonstrates strong financial performance, which is the primary driver of its overall score. While the technical analysis indicates a neutral trend, the company's solid valuation metrics support a positive outlook. The lack of significant earnings call data or notable corporate events means these factors do not affect the score.
Jefferies Analyst forecast on IN:AJANTPHARM
Alok DalalJefferies
Jefferies
₹2,850₹3,140
Buy
20.04%
Upside
Reiterated
04/30/25
Ajanta Pharma (AJP:IN) PT Raised to INR3,140 at JefferiesJefferies analyst Alok Dalal raised the price target on Ajanta Pharma (AJP:IN) to INR3,140.00 (from INR2,850.00) while maintaining a Buy rating.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ajanta Pharma Limited

1 Month
xxx
Success Rate
0/1 ratings generated profit
0%
Average Return
-1.00%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 0.00% of your transactions generating a profit, with an average return of -1.00% per trade.
3 Months
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+2.30%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +2.30% per trade.
1 Year
Alok DalalJefferies
Success Rate
1/1 ratings generated profit
100%
Average Return
+2.70%
reiterated a buy rating 3 months ago
Copying Alok Dalal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +2.70% per trade.
2 Years
xxx
Success Rate
1/1 ratings generated profit
100%
Average Return
+4.90%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +4.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AJANTPHARM Analyst Recommendation Trends

Rating
Apr 25
Jul 25
Strong Buy
0
0
Buy
2
4
Hold
0
0
Sell
0
0
Strong Sell
0
0
total
2
4
In the current month, AJANTPHARM has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AJANTPHARM average Analyst price target in the past 3 months is 3,140.00.
Each month's total comprises the sum of three months' worth of ratings.

AJANTPHARM Stock Forecast FAQ

What is IN:AJANTPHARM’s average 12-month price target, according to analysts?
Based on analyst ratings, Ajanta Pharma Limited’s 12-month average price target is 3,140.00.
    What is IN:AJANTPHARM’s upside potential, based on the analysts’ average price target?
    Ajanta Pharma Limited has 20.04% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Ajanta Pharma Limited a Buy, Sell or Hold?
          Ajanta Pharma Limited has a consensus rating of Moderate Buy, which is based on 0 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Ajanta Pharma Limited’s share price target?
            The average share price target for Ajanta Pharma Limited is 3,140.00. This is based on 0 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ₹3,140.00 ,and the lowest forecast is ₹3,140.00. The average share price target represents 20.04% Increase from the current price of ₹2,615.75.
              What do analysts say about Ajanta Pharma Limited?
              Ajanta Pharma Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 0 Wall Streets Analysts.
                How can I buy shares of Ajanta Pharma Limited?
                To buy shares of IN:AJANTPHARM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis